Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, has partnered with Polestar Technologies, a leader in optical sensing technologies since 1993, specializing in the monitoring of O2, CO2 and pH....
them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher...
LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a novel, once-monthly, LDL-cholesterol lowering, third-generation PCSK9 inhibitor, today announced positive results from two studies in the...
are committed to supplying patients with an integrated portfolio of generic, biosimilar and innovative branded pharmaceutical products.
Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), for exclusive rights to the commercialization of clobetasol...
ONFAB, a leading European provider of single-use, flexible containment solutions for the pharmaceutical industry, has officially launched business operations in the United States in conjunction with parent company Savillex. The company's American...
BioLineRx Ltd. a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem...
Regulus Therapeutics Inc. a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs today announced, after review of all available safety data, the Company initiated screening of the fourth...
Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced that the U.S. Food and Drug Administration (FDA) has approved...
avoid life-threatening bleeding episodes as well as a better quality of life." FDA orphan drug designation provides pharmaceutical manufacturers with the potential for seven years of market exclusivity, tax credits for qualified clinical trials,...
Licence issued by the New Zealand Ministry of Health. MedReleaf Australia is backed by more than 50 combined years of pharmaceutical and healthcare expertise, is driven by Research and Development, and has an exclusive strategic partnership with...
and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with...
reconcile our company and product names to show application in a wider range of industries throughout the validated pharmaceutical cold chain.” ClimateCrate operates on a manifold of high-capacity rechargeable deep-cycle lead-acid batteries....
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection...
listing for National Healthcare Insurance Reimbursement in Korea. Domestic sales of JAQBO will be handled by Jeil Pharmaceutical, Onconic Therapeutics's parent company. In March 2023, JAQBO was licensed out to Livzon Pharmaceutical Group, the...
and outcomes of medicines with its innovative delivery systems, announced the Nature publication1 of Gennova Biopharmaceutical’s Phase 2/3 clinical trial conducted to evaluate the safety and immunogenicity of its novel samRNA-based Covid-19 vaccine...
Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, announced an oral presentation on RBT-1 at the prestigious, RBT-1 (stannic protoporfin...
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, announced that the European Medicines Agency has...
Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain. Based on last year's positive mid-enrollment interim analysis and confirmed...
Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced that VIGPODER™ (vigabatrin) for oral solution, USP, a treatment for appropriate patients with...
